Literature DB >> 6424502

Synthesis of a fluorescent derivative of glucosyl ceramide for the sensitive determination of glucocerebrosidase activity.

T Dinur, G A Grabowski, R J Desnick, S Gatt.   

Abstract

A fluorescent derivative of glucosyl ceramide was synthesized by covalently linking a fluorescent fatty acid, 12-[N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)] aminododecanoic acid to the amino group of sphingosyl-1-O-beta-D-glucoside, glucosyl sphingosine. For hydrolysis by glucocerebrosidase, this substrate was dispersed in mixed micelles with Triton X-100 and sodium taurocholate or in unilamellar liposomes with phosphatidylcholine and the negatively charged lipid, dicetylphosphate. In either micellar or liposomal dispersions of the fluorescent substrate, reaction rates were linear with time and protein concentration, and saturation kinetics were observed. The rate of hydrolysis of this fluorescent substrate was equal to that obtained with radiolabeled glucosyl ceramide. The fluorescent glucosyl ceramide was used to determine glucocerebrosidase activity in extracts of human leukocytes, cultured skin fibroblasts, and various tissues as well as in partially purified splenic and placental glucocerebrosidase preparations. This fluorescent derivative of the natural substrate was not hydrolyzed by aryl beta-glucosidase(s), thereby facilitating the specific and reliable diagnosis of heterozygotes and homozygotes with Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424502     DOI: 10.1016/0003-2697(84)90329-4

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  15 in total

1.  Overexpression of human glucocerebrosidase containing different-sized leaders.

Authors:  M Pasmanik-Chor; O Elroy-Stein; H Aerts; V Agmon; S Gatt; M Horowitz
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

Review 2.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

3.  Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients.

Authors:  M E Grace; R J Desnick; G M Pastores
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

4.  Enhancement of fluorescence of pyrene-containing lipids by polar media, detergents and phospholipids.

Authors:  T Levade; R Salvayre; S Gatt
Journal:  Experientia       Date:  1987-09-15

5.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

Authors:  M E Grace; A Berg; G S He; L Goldberg; M Horowitz; G A Grabowski
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

Review 6.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

7.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

8.  A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus.

Authors:  I Z Zador; G D Deshmukh; R Kunkel; K Johnson; N S Radin; J A Shayman
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  A mouse B16 melanoma mutant deficient in glycolipids.

Authors:  S Ichikawa; N Nakajo; H Sakiyama; Y Hirabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Fluorescence assay of glucosylceramide glucosidase using NBD-cerebroside.

Authors:  A Abe; J A Shayman; N S Radin
Journal:  Lipids       Date:  1992-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.